loading
Schlusskurs vom Vortag:
$16.51
Offen:
$16.88
24-Stunden-Volumen:
9,869
Relative Volume:
0.19
Marktkapitalisierung:
$326.78M
Einnahmen:
$54,000
Nettoeinkommen (Verlust:
$-210.26M
KGV:
-21.14
EPS:
-0.79
Netto-Cashflow:
$-159.01M
1W Leistung:
-5.10%
1M Leistung:
+32.14%
6M Leistung:
+93.16%
1J Leistung:
-28.22%
1-Tages-Spanne:
Value
$16.37
$17.01
1-Wochen-Bereich:
Value
$16.37
$19.45
52-Wochen-Spanne:
Value
$7.65
$30.00

Lyell Immunopharma Inc Stock (LYEL) Company Profile

Name
Firmenname
Lyell Immunopharma Inc
Name
Telefon
650 695-0677
Name
Adresse
201 HASKINS WAY, SOUTH SAN FRANCISCO
Name
Mitarbeiter
300
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-12
Name
Neueste SEC-Einreichungen
Name
LYEL's Discussions on Twitter

Vergleichen Sie LYEL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
LYEL
Lyell Immunopharma Inc
17.01 317.18M 54,000 -210.26M -159.01M -0.79
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
406.76 104.55B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
472.17 60.36B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
551.62 59.84B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
809.47 49.07B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
331.09 35.16B 4.56B -176.77M 225.30M -1.7177

Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-10-30 Herabstufung BofA Securities Buy → Underperform
2024-06-27 Herabstufung H.C. Wainwright Buy → Neutral
2023-08-28 Herabstufung JP Morgan Overweight → Neutral
2022-11-14 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-11-11 Herabstufung Goldman Buy → Neutral
2022-10-17 Eingeleitet H.C. Wainwright Buy
2021-07-12 Eingeleitet BofA Securities Buy
2021-07-12 Eingeleitet Goldman Buy
2021-07-12 Eingeleitet JP Morgan Overweight
2021-07-12 Eingeleitet Morgan Stanley Overweight
Alle ansehen

Lyell Immunopharma Inc Aktie (LYEL) Neueste Nachrichten

pulisher
10:03 AM

Tick level data insight on Lyell Immunopharma Inc. volatilityPortfolio Value Report & Free Safe Entry Trade Signal Reports - newser.com

10:03 AM
pulisher
08:33 AM

Is it too late to sell Lyell Immunopharma Inc.Market Trend Review & Expert-Curated Trade Recommendations - newser.com

08:33 AM
pulisher
12:29 PM

How to track smart money flows in Lyell Immunopharma Inc.Portfolio Gains Report & Consistent Income Trade Ideas - newser.com

12:29 PM
pulisher
Oct 10, 2025

Is Lyell Immunopharma Inc. showing signs of accumulationMarket Movement Recap & Expert Curated Trade Setup Alerts - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Is Lyell Immunopharma Inc. forming a reversal pattern2025 Market WrapUp & Long-Term Capital Growth Strategies - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Lyell Immunopharma (NASDAQ:LYEL) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Will Lyell Immunopharma Inc. continue its uptrend2025 Market Outlook & Risk Managed Investment Signals - newser.com

Oct 10, 2025
pulisher
Oct 08, 2025

Clarius Group LLC Reduces Stake in Lyell Immunopharma, Inc. $LYEL - MarketBeat

Oct 08, 2025
pulisher
Oct 06, 2025

Can trapped investors hope for a rebound in Lyell Immunopharma Inc.Long Setup & Technical Pattern Alert System - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Johnson & Johnson Reduces Stock Holdings in Lyell Immunopharma, Inc. $LYEL - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

Smart tools for monitoring Lyell Immunopharma Inc.’s price actionPortfolio Update Summary & Long-Term Safe Investment Plans - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

News impact scoring models applied to Lyell Immunopharma Inc.July 2025 Fed Impact & Technical Buy Zone Confirmations - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Technical analysis overview for Lyell Immunopharma Inc. stockGlobal Markets & High Conviction Trade Alerts - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Trend analysis for Lyell Immunopharma Inc. this weekProduct Launch & Free Community Supported Trade Ideas - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Applying chart zones and confluence areas to Lyell Immunopharma Inc.Earnings Overview Report & Capital Efficiency Focused Strategies - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Will Lyell Immunopharma Inc. stock deliver long term returns2025 Earnings Impact & High Accuracy Investment Signals - newser.com

Oct 05, 2025
pulisher
Oct 02, 2025

Using Ichimoku Cloud for Lyell Immunopharma Inc. technicals2025 Stock Rankings & Community Trade Idea Sharing Platform - newser.com

Oct 02, 2025
pulisher
Oct 02, 2025

How moving averages guide Lyell Immunopharma Inc. tradingPortfolio Growth Summary & High Accuracy Swing Entry Alerts - newser.com

Oct 02, 2025
pulisher
Oct 02, 2025

Voya Investment Management LLC Sells 2,606 Shares of Lyell Immunopharma, Inc. $LYEL - Defense World

Oct 02, 2025
pulisher
Sep 30, 2025

Applying Elliott Wave Theory to Lyell Immunopharma Inc.Market Risk Analysis & Consistent Profit Trading Strategies - newser.com

Sep 30, 2025
pulisher
Sep 29, 2025

Goldman Sachs Group Inc. Has $193,000 Position in Lyell Immunopharma, Inc. $LYEL - Defense World

Sep 29, 2025
pulisher
Sep 29, 2025

What’s the recovery path for long term holders of Lyell Immunopharma Inc.Weekly Loss Report & Consistent Return Investment Signals - newser.com

Sep 29, 2025

Finanzdaten der Lyell Immunopharma Inc-Aktie (LYEL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Lyell Immunopharma Inc-Aktie (LYEL) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Hill Stephen J.
Chief Operating Officer
Aug 21 '25
Sale
10.54
1,004
10,586
15,845
Newton Charles W.
Chief Financial Officer
Aug 21 '25
Sale
10.54
1,453
15,320
15,306
Lee Gary K.
Chief Scientific Officer
Aug 21 '25
Sale
10.54
1,453
15,320
15,504
Seely Lynn
President and CEO
Aug 12 '25
Sale
10.34
406
4,197
34,828
Seely Lynn
President and CEO
Aug 11 '25
Sale
10.53
391
4,116
35,234
Hill Stephen J.
Chief Operating Officer
Aug 12 '25
Sale
10.34
94
972
8,849
Hill Stephen J.
Chief Operating Officer
Aug 11 '25
Sale
10.53
91
958
8,943
Lee Gary K.
Chief Scientific Officer
Aug 12 '25
Sale
10.34
136
1,406
8,957
Lee Gary K.
Chief Scientific Officer
Aug 11 '25
Sale
10.53
131
1,379
9,093
Newton Charles W.
Chief Financial Officer
Aug 12 '25
Sale
10.34
136
1,406
8,759
$84.60
price up icon 0.95%
$22.86
price up icon 6.98%
$32.47
price up icon 2.06%
$102.55
price up icon 0.63%
$166.10
price up icon 2.22%
biotechnology ONC
$331.09
price up icon 3.45%
Kapitalisierung:     |  Volumen (24h):